Genentech Loses Eye-Drug Patent Rights Over Agent's Error
The Court of Appeal ruled Tuesday that Genentech Inc. can't correct a mistake made by one of its agents that will prematurely end its patent rights for an eye-disease treatment, saying...To view the full article, register now.
Already a subscriber? Click here to view full article